期刊文献+

唑来膦酸治疗类风湿关节炎继发骨质疏松患者的临床分析 被引量:8

Clinical analysis of the effect of zoledronic acid for the treatment of secondary osteoporosis in patients with rheumatoid arthritis
下载PDF
导出
摘要 目的通过对类风湿关节炎继发骨质疏松患者,给予唑来膦酸的治疗,观察及分析治疗后的临床指标,评价唑来膦酸的疗效及安全性。方法所有患者均静脉输注5 mg唑来膦酸注射液,第6、12个月回访,复查DXA、ESR、血清RF、CRP,以及通过FRAX计算未来10年的髋部骨折概率。结果腰3、Ward区、大转子、股骨颈12个月时BMD与治疗前相比存在统计学差异,其余虽无统计学意义,但存在提高的趋势。未口服激素的RA病人在12个月时髋骨骨折概率与治疗前相比存在统计学差异。合并OP的RA病人在应用唑来膦酸后,随着治疗的进行,炎性指标下降,病情活动评分下降,血沉和C反应蛋白与治疗前对比有统计学意义。结论唑来膦酸能在短期内有效改善类风湿关节炎继发骨质疏松的骨质量,提高骨密度,减低骨折概率,并对类风湿病情活动有一定的抑制作用。 Objectives By using zoledronic acid for the treatment of secondary osteoporosis (OP) in patients with rheumatoid arthritis (RA), to observe and analyze the clinic indexes of paitents after the treatment, and to evaluate the clinical efficacy and safety of zoledronic acid. Methods All the patients were given an intravenous infusion of 5mg zoledronie acid. The follow-ups were performed at the 6th month and the 12th month after the treatment. DXA, ESR, serum RF, and CRP was detected. The probability of the hip fractures in the next 10 years was calculated using FRAX. Result BMD of L 3, zone Ward, trochanter, femoral neck at 12 months compared with those before treatment is significant. The rest had no significant difference, but there is an increasing trend. In without oral hormone group with RA, hip fracture probability of 12 months compared with those before treatment is significant. For OP patients with RA zoledronic acid treatment would decrease disease activity score28, ESR and CRP, and it is significant compared with before treatment. Conclusion Zoledronie acid can significantly improve the bone quality, improve bone mineral density, and reduce the probability of fractures in RA paitents with secondary OP in a short term. It also has certain inhibiting effect on the activity of rheumatoid.
机构地区 大庆油田总医院
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2013年第10期1056-1058,共3页 Chinese Journal of Osteoporosis
关键词 唑来膦酸 类风湿关节炎 骨质疏松症 FRAX Zoledronic acid Rheumatoid arthritis Osteoporosis FRAX
  • 相关文献

参考文献7

二级参考文献51

  • 1余传林,陈卫民,徐伟,徐继红,刘叔文,吴曙光.国产羟乙膦酸二钠治疗骨质疏松症180例临床验证报告[J].中国骨质疏松杂志,1997,3(2):52-55. 被引量:6
  • 2杨春莉,裘宇容,周芳,李娟.对比检测血清中抗环瓜氨酸肽抗体水平对类风湿关节炎的诊断价值[J].南方医科大学学报,2007,27(8):1277-1279. 被引量:18
  • 3Gatromanolaki A,Sivridis E,Mahezos E,et al.Upregulated hypoxia indueible factor-1 alpha and HIF-2 alpha pathway in rheumatoid arthritis and osteoarthritis[J].Arthritis Res Ther,2003,5(4):193.
  • 4Curtis J R,McClure L A,Delzell E,et al.Population-Based fracture risk assessment and osteoporosis treatment disparities by race and gender[J].J Gen Intern Med,2009,24(8):956.
  • 5Daniel H,Solomon,Joel S,Finkelstein,et al.The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis:The osteoporosis in rheumatoid arthritis (OPiRA) cohort study[J].Arthritis Rheum,2009,60(6):1624.
  • 6Hollander A P,CoAe K P,Freemont A J,et al.Expression of hypoxia inducible factor 1 alpha by macrophages in the rheumatoid synovium:implications for targeting of therapeutic genes to the inflamed joint[J].Arthritis Rheum,2001,44(7):1540.
  • 7Drugs of Future,2000,25(3):259-268.
  • 8邱贵兴,赵宇.双膦酸盐在骨质疏松症中的应用.见:郭世绂,罗先正,邱贵兴,主编.骨质疏松基础与临床.第1版.天津:天津科学技术出版社,2001:503-512.
  • 9Katamura Y,Aikata H,Hashimoto Y,et al.Zoledronic aciddelays disease progression of bone metastases from hepatocellularcarcinoma.Hepatol Res,2010,7(10):1195-1203.
  • 10Eidtmann H,de Boer R,Bundred N,et al.Efficacy of zoledronicacid in postmenopausal women with early breast cancer receivingadjuvant letrozole:36-month results of the ZO-FAST Study.AnnOncol,2010,21(11):2188-2194.

共引文献68

同被引文献71

  • 1朱欢丽,刘晓晴,夏秦.运动对老年骨质疏松症患者骨量和骨代谢影响的研究[J].中国妇幼保健,2007,22(9):1251-1252. 被引量:28
  • 2唐佩福,姚琦.骨质疏松性股骨颈骨折的研究现状[J].中国骨肿瘤骨病,2007,6(2):110-113. 被引量:10
  • 3路微波,胡永善,吴毅,白玉龙,吴军发,孙宏伟.老年骨质疏松性股骨粗隆间骨折围手术期运动疗法干预研究[J].中国康复医学杂志,2007,22(7):612-614. 被引量:15
  • 4叶超群,陈佑学,纪树荣.骨质疏松性骨折的危险因素及预测[J].中国康复医学杂志,2007,22(7):660-664. 被引量:16
  • 5Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double- blind study in 100 patients [J]. Acta Orthop, 2005, 76(3): 314- 319.
  • 6Zhou XD, Tao LJ, Li J, et al. Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials [J]. Arch Orthop Trauma Surg, 2013, 133(7): 1017-1027.
  • 7Bongartz T, Halligan CS, Osmon DR, et al. IncidenCe and risk fac- tors of prosthetic joint infection after total hip or knee replace- ment in patients with rheumatoid arthritis [J]. Arthritis Rheum, 2008, 59(12): 1713-1720.
  • 8Goodman SM, Figgie M. Lower extremity arthroplasty in patients with inflammatory arthritis: preoperative and perioperative man- agement[J]. J Am Acad Orthop Surg, 2013, 21(6): 355-363.
  • 9Stundner O, Chiu YL, Sun X, et al. Perioperative outcomes in pa- tients with rheumatoid versus osteoarthritis for total hip arthro- plasty: a population-based study [J]. Clin Exp Rheumatol, 2013, 31(6): 889-895.
  • 10Gross JB. Estimating allowable blood loss: corrected for dilution [J ]. Anesthesiology, 1983, 58(3): 277-280.

引证文献8

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部